

Premal H Thaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2666914/publications.pdf>

Version: 2024-02-01

100
papers

2,862
citations

279798

23
h-index

182427

51
g-index

102
all docs

102
docs citations

102
times ranked

4173
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 379-389. | 0.8 | 28 |
| 2 | GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. <i>Molecular Cancer Research</i> , 2022, 20, 265-279. | 3.4 | 19 |
| 3 | Development of Delivery Systems for Local Administration of Cytokines/Cytokine Gene-Directed Therapeutics: Modern Oncologic Implications. <i>Current Oncology Reports</i> , 2022, 24, 389-397. | 4.0 | 5 |
| 4 | Genomic analysis of clear cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5548-5548. | 1.6 | 0 |
| 5 | HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): Defining incidence, molecular profiles, and outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5588-5588. | 1.6 | 0 |
| 6 | Real-world trends of PARPi maintenance treatment uptake and progression-free survival (PFS) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the United States.. <i>Journal of Clinical Oncology</i> , 2022, 40, 6580-6580. | 1.6 | 1 |
| 7 | Exploring the nuances between BRCA1 and 2: A multiomic analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5580-5580. | 1.6 | 0 |
| 8 | HER2 in uterine carcinosarcoma: Testing platforms and implications for targeted therapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5590-5590. | 1.6 | 0 |
| 9 | Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer. , 2021, , . | | 0 |
| 10 | The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2021, 35, 100694. | 0.6 | 3 |
| 11 | Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5566-5566. | 1.6 | 0 |
| 12 | Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?. <i>Journal of Clinical Oncology</i> , 2021, 39, e18710-e18710. | 1.6 | 0 |
| 13 | Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18693-e18693. | 1.6 | 1 |
| 14 | Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5588-5588. | 1.6 | 1 |
| 15 | NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11506-11506. | 1.6 | 9 |
| 16 | Real-world progression-free survival among patients with newly diagnosed advanced ovarian cancer: Does maintenance therapy work?. <i>Journal of Clinical Oncology</i> , 2021, 39, e18707-e18707. | 1.6 | 0 |
| 17 | Impact of employment and insurance status on distress in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2021, 161, 477-482. | 1.4 | 6 |
| 18 | A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy. <i>Gynecologic Oncology</i> , 2021, 161, 700-704. | 1.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors. <i>Scientific Reports</i> , 2021, 11, 11595. | 3.3 | 13 |
| 20 | The Role of Psychologic Stress in Cancer Initiation: Clinical Relevance and Potential Molecular Mechanisms. <i>Cancer Research</i> , 2021, 81, 5131-5140. | 0.9 | 18 |
| 21 | GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. <i>Clinical Cancer Research</i> , 2021, 27, 5536-5545. | 7.0 | 15 |
| 22 | Rural residence is related to shorter survival in epithelial ovarian cancer patients. <i>Gynecologic Oncology</i> , 2021, 163, 22-28. | 1.4 | 16 |
| 23 | Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018. <i>Future Oncology</i> , 2021, 17, 4263-4274. | 2.4 | 3 |
| 24 | Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 254-261. | 1.4 | 14 |
| 25 | Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial. <i>Gynecologic Oncology</i> , 2021, 162, 770-777. | 1.4 | 9 |
| 26 | Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?. <i>Journal of Clinical Oncology</i> , 2021, 39, 294-294. | 1.6 | 0 |
| 27 | Treatment patterns among patients with advanced/recurrent endometrial cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2021, 39, 291-291. | 1.6 | 0 |
| 28 | Assessing comprehensive care deficits in United States (U.S.) ovarian cancer programs to inform quality improvement initiatives.. <i>Journal of Clinical Oncology</i> , 2021, 39, 256-256. | 1.6 | 0 |
| 29 | Encyclopedia of endometriosis: a pictorial rad-path review. <i>Abdominal Radiology</i> , 2020, 45, 1587-1607. | 2.1 | 20 |
| 30 | Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation. <i>Cell Death and Disease</i> , 2020, 11, 842. | 6.3 | 30 |
| 31 | Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation. <i>Cancer</i> , 2020, 126, 4407-4413. | 4.1 | 15 |
| 32 | A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education. <i>Gynecologic Oncology</i> , 2020, 159, 209-213. | 1.4 | 3 |
| 33 | State of the science: Uterine sarcomas: From pathology to practice. <i>Gynecologic Oncology</i> , 2020, 159, 3-7. | 1.4 | 6 |
| 34 | Long-term outcomes of intensity-modulated radiation therapy (IMRT) and high dose rate brachytherapy as adjuvant therapy after radical hysterectomy for cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1157-1161. | 2.5 | 10 |
| 35 | Adenomyosis presenting as a molar pregnancy: A case report. <i>Gynecologic Oncology Reports</i> , 2020, 32, 100573. | 0.6 | 0 |
| 36 | Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision. <i>Gynecologic Oncology</i> , 2020, 157, 287-292. | 1.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival. <i>Gynecologic Oncology</i> , 2020, 157, 639-643. | 1.4 | 57 |
| 38 | Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3014-3014. | 1.6 | 7 |
| 39 | NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS11570-TPS11570. | 1.6 | 4 |
| 40 | Effect on response to neoadjuvant chemotherapy in high-grade serous ovarian cancer by inhibiting the GAS6/AXL pathway and inducing homologous recombination deficiency. <i>Journal of Clinical Oncology</i> , 2020, 38, 6080-6080. | 1.6 | 0 |
| 41 | Prospective study of an AI enabled online intervention to increase delivery of guideline compliant cancer care, on the ground. <i>Journal of Clinical Oncology</i> , 2020, 38, 2011-2011. | 1.6 | 1 |
| 42 | Effect of inducing HR deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor, on response to olaparib in uterine serous cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, e18108-e18108. | 1.6 | 0 |
| 43 | Patients with endometrial cancer continue to lack understanding of their risks for cancer. <i>Gynecologic Oncology Reports</i> , 2019, 29, 106-110. | 0.6 | 6 |
| 44 | Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6-year follow-up study. <i>Gynecologic Oncology</i> , 2019, 155, 88-92. | 1.4 | 10 |
| 45 | Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. <i>Gynecologic Oncology</i> , 2019, 154, 524-530. | 1.4 | 24 |
| 46 | Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 155, 39-50. | 1.4 | 16 |
| 47 | Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1088-1097. | 0.8 | 57 |
| 48 | Palliative Care in Gynecologic Oncology. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 179-197. | 1.9 | 12 |
| 49 | Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?. <i>Gynecologic Oncology Reports</i> , 2019, 29, 20-24. | 0.6 | 2 |
| 50 | Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 136-140. | 0.6 | 6 |
| 51 | Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?. <i>Gynecologic Oncology Reports</i> , 2019, 28, 1-5. | 0.6 | 4 |
| 52 | Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients. <i>Psychoneuroendocrinology</i> , 2019, 106, 244-251. | 2.7 | 14 |
| 53 | Impact of tumor histology on detection of pelvic and para-aortic nodal metastasis with ¹⁸ F-fluorodeoxyglucose-positron emission tomography in stage IB cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1351-1354. | 2.5 | 8 |
| 54 | Gynecologic Oncologists'™ Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology. <i>Gynecologic and Obstetric Investigation</i> , 2019, 84, 50-55. | 1.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | GEN-1 immunotherapy for the treatment of ovarian cancer. <i>Future Oncology</i> , 2019, 15, 421-438. | 2.4 | 11 |
| 56 | Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 389-398. | 4.1 | 32 |
| 57 | Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. <i>Gynecologic Oncology</i> , 2019, 152, 416-425. | 1.4 | 31 |
| 58 | Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5547-5547. | 1.6 | 2 |
| 59 | Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5590-5590. | 1.6 | 1 |
| 60 | Effect of therapeutic GAS6/AXL inhibition of tumor and stromal cells on DNA damage and response to chemotherapy in ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14676-e14676. | 1.6 | 2 |
| 61 | Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2-2. | 1.6 | 5 |
| 62 | Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5548-5548. | 1.6 | 1 |
| 63 | A rare case of endometrial cancer metastatic to the uveal choroid. <i>Gynecologic Oncology Reports</i> , 2018, 23, 24-27. | 0.6 | 3 |
| 64 | Changes in spiritual well-being and psychological outcomes in ovarian cancer survivors. <i>Psycho-Oncology</i> , 2018, 27, 477-483. | 2.3 | 22 |
| 65 | Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma. <i>Cancer</i> , 2018, 124, 580-586. | 4.1 | 27 |
| 66 | Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 219, 459.e1-459.e11. | 1.3 | 12 |
| 67 | SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth. <i>Gynecologic Oncology</i> , 2018, 151, 337-344. | 1.4 | 3 |
| 68 | Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. <i>Cancer</i> , 2018, 124, 3401-3408. | 4.1 | 23 |
| 69 | Identification of molecular targets in vulvar cancers. <i>Gynecologic Oncology</i> , 2017, 146, 305-313. | 1.4 | 26 |
| 70 | A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 145, 291-297. | 1.4 | 15 |
| 71 | Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw251. | 6.3 | 28 |
| 72 | Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2881-2891. | 4.1 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | The effect of a multidisciplinary palliative care initiative on end of life care in gynecologic oncology patients. <i>Gynecologic Oncology</i> , 2017, 147, 460-464. | 1.4 | 10 |
| 74 | A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017, 147, 283-290. | 1.4 | 37 |
| 75 | Reply. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 192-193. | 1.3 | 0 |
| 76 | Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 156-156. | 1.6 | 0 |
| 77 | Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 155-155. | 1.6 | 1 |
| 78 | Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. <i>Gynecologic Oncology</i> , 2016, 142, 76-82. | 1.4 | 26 |
| 79 | Stress and burnout among gynecologic oncologists: A Society of Gynecologic Oncology Evidence-based Review and Recommendations. <i>Gynecologic Oncology</i> , 2016, 143, 421-427. | 1.4 | 40 |
| 80 | Adult Comorbidity Evaluation 27 score as a predictor of survival in endometrial cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 766.e1-766.e9. | 1.3 | 23 |
| 81 | Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?. <i>Cancer</i> , 2016, 122, 325-326. | 4.1 | 4 |
| 82 | Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. <i>Gynecologic Oncology</i> , 2016, 141, 134-139. | 1.4 | 37 |
| 83 | Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS5605-TPS5605. | 1.6 | 1 |
| 84 | AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. <i>Oncotarget</i> , 2016, 7, 77291-77305. | 1.8 | 26 |
| 85 | Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. <i>Cancer</i> , 2015, 121, 3444-3451. | 4.1 | 157 |
| 86 | Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer. <i>Cancer</i> , 2015, 121, 3543-3550. | 4.1 | 15 |
| 87 | Diurnal cortisol and survival in epithelial ovarian cancer. <i>Psychoneuroendocrinology</i> , 2015, 53, 256-267. | 2.7 | 76 |
| 88 | Awareness of the association between obesity and peri-operative risk among newly diagnosed patients with complex atypical hyperplasia and endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2015, 12, 41-44. | 0.6 | 3 |
| 89 | A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 30-35. | 1.4 | 57 |
| 90 | A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2015, 138, 36-40. | 1.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. <i>Gynecologic Oncology</i> , 2015, 137, 7-13. | 1.4 | 47 |
| 92 | A comparison of monthly symptom reports for older (≥ 70 years) versus younger (< 70 years) women with recurrent ovarian cancer over 1 year.. <i>Journal of Clinical Oncology</i> , 2015, 33, 85-85. | 1.6 | 2 |
| 93 | A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2014, 133, 537-541. | 1.4 | 31 |
| 94 | Importance of adrenergic pathways in women's cancers. <i>Cancer Biomarkers</i> , 2013, 13, 145-154. | 1.7 | 16 |
| 95 | Neuroendocrine influences on cancer biology. <i>Seminars in Cancer Biology</i> , 2008, 18, 164-170. | 9.6 | 81 |
| 96 | The Neuroendocrine Impact of Chronic Stress on Cancer. <i>Cell Cycle</i> , 2007, 6, 430-433. | 2.6 | 125 |
| 97 | Value of HPV testing in follow-up of treated high-risk CIN1: a study by Alonso et al. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 433-434. | 1.3 | 1 |
| 98 | Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. <i>Nature Medicine</i> , 2006, 12, 939-944. | 30.7 | 1,029 |
| 99 | Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal. <i>Cancer Biology and Therapy</i> , 2005, 4, 753-758. | 3.4 | 39 |
| 100 | EphA2 Expression Is Associated with Aggressive Features in Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 5145-5150. | 7.0 | 197 |